Herpes Reason 5 O O
zoster Reason 5 O O
is Reason 5 O O
a Reason 5 O O
serious Reason 5 O O
health Reason 5 O O
problem Reason 5 O O
in Reason 5 O O
the Reason 5 O O
United Reason 5 O O
States. Reason 5 O O
Current O O O O
estimates O O O O
of O O O O
new O O O O
cases O O O O
in O O O O
the O O O O
US O O O O
are O O O O
up O O O O
to O O O O
1.2 O O O O
million O O O O
annually, O O O O
about O O O O
20% O O O O
of O O O O
which O O O O
are O O O O
herpes O O O O
zoster O O O O
ophthalmicus O O O O
(HZO). O O O O
It O O O O
is O O O O
estimated O O O O
that O O O O
1 O O O O
in O O O O
3 O O O O
people O O O O
will O O O O
have O O O O
herpes O O O O
zoster O O O O
in O O O O
their O O O O
lifetime. O O O O
Although Reason 3 O O
the Reason 3 O O
incidence Reason 3 O O
of Reason 3 O O
herpes Reason 3 O O
zoster Reason 3 O O
goes Reason 3 O O
up Reason 3 O O
significantly Reason 3 O O
with Reason 3 O O
age, Reason 3 O O
starting Reason 3 O O
at Reason 3 O O
40 Reason 3 O O
years, Reason 3 O O
the Reason 3 O O
number Reason 3 O O
of Reason 3 O O
cases Reason 3 O O
is Reason 3 O O
highest Reason 3 O O
in Reason 3 O O
people Reason 3 O O
50 Reason 3 O O
to Reason 3 O O
59 Reason 3 O O
years Reason 3 O O
of Reason 3 O O
age. Reason 3 O O
In Reason 3 O O
one Reason 3 O O
Centers Reason 3 O O
for Reason 3 O O
Disease Reason 3 O O
Control Reason 3 O O
and Reason 3 O O
Prevention Reason 3 O O
(CDC) Reason 3 O O
study, Reason 3 O O
the Reason 3 O O
mean Reason 3 O O
age Reason 3 O O
of Reason 3 O O
onset Reason 3 O O
was Reason 3 O O
52 Reason 3 O O
years. Reason 3 O O
Risk Reason 3 O O
factors Reason 3 O O
for Reason 3 O O
the Reason 3 O O
development Reason 3 O O
of Reason 3 O O
herpes Reason 3 O O
zoster Reason 3 O O
include Reason 3 O O
increased Reason 3 O O
age, Reason 3 O O
immunocompromised Reason 3 O O
status, Reason 3 O O
female Reason 3 O O
gender, Reason 3 O O
severe Reason 3 O O
physical Reason 3 O O
limitation, Reason 3 O O
heart Reason 3 O O
failure, Reason 3 O O
traumatic Reason 3 O O
brain Reason 3 O O
injury, Reason 3 O O
diabetes, Reason 3 O O
acute Reason 3 O O
kidney Reason 3 O O
failure, Reason 3 O O
and Reason 3 O O
depression. Reason 3 O O
The Reason 3 O O
complications Reason 3 O O
and Reason 3 O O
sequelae Reason 3 O O
of Reason 3 O O
herpes Reason 3 O O
zoster Reason 3 O O
can Reason 3 O O
be Reason 3 O O
severe Reason 3 O O
and Reason 3 O O
long Reason 3 O O
term, Reason 3 O O
even Reason 3 O O
-- Reason 3 O O
rarely Reason 3 O O
-- Reason 3 O O
resulting Reason 3 O O
in Reason 3 O O
death. Reason 3 O O
The Reason 3 O O
medical Reason 3 O O
costs Reason 3 O O
caused Reason 3 O O
by Reason 3 O O
herpes Reason 3 O O
zoster Reason 3 O O
and Reason 3 O O
it Reason 3 O O
complications, Reason 3 O O
including Reason 3 O O
direct Reason 3 O O
medical Reason 3 O O
care Reason 3 O O
costs Reason 3 O O
from Reason 3 O O
acute Reason 3 O O
and Reason 3 O O
chronic Reason 3 O O
pain, Reason 3 O O
eye Reason 3 O O
complications, Reason 3 O O
secondary Reason 3 O O
infections Reason 3 O O
and Reason 3 O O
neuropathies, Reason 3 O O
are Reason 3 O O
estimated Reason 3 O O
to Reason 3 O O
be Reason 3 O O
$1 Reason 3 O O
billion, Reason 3 O O
with Reason 3 O O
indirect Reason 3 O O
costs Reason 3 O O
from Reason 3 O O
lost Reason 3 O O
work Reason 3 O O
and Reason 3 O O
work Reason 3 O O
productivity Reason 3 O O
adding Reason 3 O O
to Reason 3 O O
that Reason 3 O O
total, Reason 3 O O
especially Reason 3 O O
in Reason 3 O O
younger Reason 3 O O
age Reason 3 O O
groups Reason 3 O O
such Reason 3 O O
as Reason 3 O O
those Reason 3 O O
50 Reason 3 O O
to Reason 3 O O
59 Reason 3 O O
years Reason 3 O O
of Reason 3 O O
age. Reason 3 O O
A Reason 4 O O
randomized, Reason 4 O O
controlled Reason 4 O O
clinical Reason 4 O O
trial Reason 4 O O
demonstrated Reason 4 O O
that Reason 4 O O
zoster Reason 4 O O
vaccine Reason 4 O O
live Reason 4 O O
(ZVL; Reason 4 O O
an Reason 4 O O
attenuated Reason 4 O O
live Reason 4 O O
virus Reason 4 O O
vaccine; Reason 4 O O
Zostavax; Reason 4 O O
Merck Reason 4 O O
& Reason 4 O O
Co, Reason 4 O O
Inc, Reason 4 O O
Whitehouse Reason 4 O O
Station, Reason 4 O O
NJ) Reason 4 O O
decreased Reason 4 O O
the Reason 4 O O
incidence Reason 4 O O
of Reason 4 O O
herpes Reason 4 O O
zoster Reason 4 O O
by Reason 4 O O
51% Reason 4 O O
and Reason 4 O O
the Reason 4 O O
occurrence Reason 4 O O
of Reason 4 O O
postherpetic Reason 4 O O
neuralgia Reason 4 O O
by Reason 4 O O
66% Reason 4 O O
in Reason 4 O O
immunocompetent Reason 4 O O
people Reason 4 O O
60 Reason 4 O O
years Reason 4 O O
of Reason 4 O O
age Reason 4 O O
and Reason 4 O O
older. Reason 4 O O
The Reason 5 O O
recombinant Reason 5 O O
zoster Reason 5 O O
vaccine Reason 5 O O
(RZV; Reason 5 O O
PA) Reason 5 O O
also Reason 5 O O
called Reason 5 O O
vaccine, Reason 5 O O
contains Reason 5 O O
a Reason 5 O O
recombinant Reason 5 O O
varicella Reason 5 O O
zoster Reason 5 O O
virus Reason 5 O O
glycoprotein Reason 5 O O
E Reason 5 O O
surface Reason 5 O O
antigen Reason 5 O O
reconstituted Reason 5 O O
in Reason 5 O O
a Reason 5 O O
novel Reason 5 O O
liposome-based Reason 5 O O
adjuvant Reason 5 O O
system. Reason 5 O O
A Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
(Zoster Reason 5 O O
Efficacy Reason 5 O O
Study Reason 5 O O
in Reason 5 O O
Adults Reason 5 O O
50 Reason 5 O O
Years Reason 5 O O
of Reason 5 O O
Age Reason 5 O O
or Reason 5 O O
Older Reason 5 O O
[ZOE-50]) Reason 5 O O
of Reason 5 O O
the Reason 5 O O
RZV Reason 5 O O
compared Reason 5 O O
with Reason 5 O O
placebo Reason 5 O O
conducted Reason 5 O O
outside Reason 5 O O
of Reason 5 O O
the Reason 5 O O
United Reason 5 O O
States Reason 5 O O
from Reason 5 O O
2010 Reason 5 O O
through Reason 5 O O
2011, Reason 5 O O
the Reason 5 O O
results Reason 5 O O
of Reason 5 O O
which Reason 5 O O
were Reason 5 O O
published Reason 5 O O
in Reason 5 O O
2015, Reason 5 O O
demonstrated Reason 5 O O
that Reason 5 O O
this Reason 5 O O
vaccine Reason 5 O O
had Reason 5 O O
an Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
approximately Reason 5 O O
97% Reason 5 O O
in Reason 5 O O
all Reason 5 O O
age Reason 5 O O
groups. Reason 5 O O
The Reason 5 O O
results Reason 5 O O
of Reason 5 O O
the Reason 5 O O
second Reason 5 O O
part Reason 5 O O
of Reason 5 O O
this Reason 5 O O
trial Reason 5 O O
(Zoster Reason 5 O O
Efficacy Reason 5 O O
Study Reason 5 O O
in Reason 5 O O
Adults Reason 5 O O
70 Reason 5 O O
Years Reason 5 O O
of Reason 5 O O
Age Reason 5 O O
or Reason 5 O O
Older Reason 5 O O
[ZOE-70]), Reason 5 O O
which Reason 5 O O
was Reason 5 O O
conducted Reason 5 O O
concurrently Reason 5 O O
and Reason 5 O O
included Reason 5 O O
participants Reason 5 O O
70 Reason 5 O O
years Reason 5 O O
of Reason 5 O O
age Reason 5 O O
and Reason 5 O O
older, Reason 5 O O
were Reason 5 O O
pooled Reason 5 O O
with Reason 5 O O
ZOE-50 Reason 5 O O
and Reason 5 O O
showed Reason 5 O O
an Reason 5 O O
approximately Reason 5 O O
90% Reason 5 O O
efficacy Reason 5 O O
in Reason 5 O O
vaccine Reason 5 O O
recipients Reason 5 O O
70 Reason 5 O O
years Reason 5 O O
of Reason 5 O O
age Reason 5 O O
and Reason 5 O O
older. Reason 5 O O
